|1.||Kurumatani, Hajimu: 8 articles (01/2015 - 08/2002)|
|2.||Tamura, Mitsutaka: 4 articles (08/2014 - 08/2002)|
|3.||Nagaya, Noritoshi: 4 articles (11/2006 - 05/2003)|
|4.||Miyamoto, Mitsuko: 3 articles (08/2014 - 09/2006)|
|5.||Sato, Nahoko: 3 articles (08/2013 - 08/2002)|
|6.||Nakanishi, Norifumi: 3 articles (01/2004 - 05/2003)|
|7.||Origasa, Hideki: 2 articles (01/2015 - 01/2014)|
|8.||Lin, Heng: 2 articles (01/2015 - 09/2010)|
|9.||Okada, Kiyonobu: 2 articles (01/2015 - 01/2014)|
|10.||Fujita, Toshiro: 2 articles (01/2015 - 01/2014)|
|1.||Pulmonary Hypertension (Ayerza Syndrome)
10/01/2005 - "These data also suggest that beraprost, which is clinically effective in treating pulmonary hypertension, may have therapeutic potential for preventing hepatic injury."
01/01/2011 - "Persistent pulmonary hypertension of the newborn successfully treated with beraprost sodium: a retrospective chart review."
06/01/2008 - "Beraprost sodium (BPS) is often used for pediatric patients with pulmonary hypertension. "
03/01/2006 - "In our case, cardiac catetherization revealed a remaining of pulmonary hypertension under medication of beraprost sodium. "
04/01/2004 - "[Effect of long-term therapy with oral Beraprost on survival of patients with arterial and inoperable thromboembolic pulmonary hypertension]."
|2.||Peripheral Arterial Disease
06/01/2013 - "Ninety-four diabetic patients with peripheral arterial disease were treated with Beraprost in a fixed-dose, prospective, multicenter, cohort study. "
06/01/2013 - "Effects of Beraprost sodium on subjective symptoms in diabetic patients with peripheral arterial disease."
04/01/2010 - "To date, beraprost has been used in the treatment of PAH and peripheral arterial disease (PAD). "
06/01/2013 - "This study evaluated the effects of Beraprost sodium (Berasil) on subjective leg symptoms in patients with peripheral arterial disease caused by diabetes mellitus. "
01/01/2002 - "Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension."
|3.||Systemic Scleroderma (Systemic Sclerosis)
07/01/2002 - "This study showed that DLCO levels in patients with systemic sclerosis improved after the administration of beraprost sodium, probably due to the decrease in pulmonary vascular resistance accompanied by increased cardiac output."
10/01/1999 - "To compare the efficacy of 6 to 12 months of beraprost sodium (BPS) therapy with placebo in the prevention of digital ulceration in patients with systemic sclerosis (SSc). "
02/01/1995 - "[Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis]."
07/01/2002 - "The objective of this study was to assess the effect of beraprost sodium, an oral prostacyclin analogue, on pulmonary function in patients with systemic sclerosis. "
07/01/2002 - "Seventeen patients, with systemic sclerosis and predicted percent values of carbon monoxide diffusion capacity (%DLCO) of less than 95, received beraprost sodium for at least 12 months. "
01/01/2002 - "In patients with intermittent claudication, significant benefits of beraprost compared with placebo were reported in a randomised clinical trial; however, the use of beraprost in these patients is not supported by recent preliminary unpublished data from a large, phase III, placebo-controlled study. "
05/21/2003 - "In the current study, we hypothesized that beraprost would: 1) improve treadmill exercise performance and quality of life; and 2) decrease rates of ischemic events in patients with intermittent claudication. "
06/01/1996 - "A dose-effect study of beraprost sodium in intermittent claudication."
05/21/2003 - "Despite previous investigations suggesting efficacy, these results indicate that beraprost is not an effective treatment to improve symptoms of intermittent claudication in patients with PAD. "
05/21/2003 - "Patients with intermittent claudication (n = 897) were randomized to receive either 40 microg three times a day of beraprost with meals (n = 385) or placebo (n = 377) in a double-blinded manner for one year. "
08/01/1997 - "In clinical studies, beraprost sodium exerted a marked effect to improve arteriosclerosis obliterans. "
05/01/2013 - "Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients."
01/01/2015 - "Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study."
01/01/2002 - "Additional well-designed and, where possible, large trials with active comparators are necessary to define more precisely the place of beraprost in the treatment of patients with PAH, Buerger's disease and arteriosclerosis obliterans."
01/01/2002 - "Beraprost, an orally administered PGI2 analogue, is generally well tolerated and appears to be an effective agent in the treatment of patients with Buerger's disease and arteriosclerosis obliterans. "
|2.||Idiopathic pulmonary hypertension
|5.||Vasodilator Agents (Vasodilators)
|10.||GTP Phosphohydrolases (GTPases)
|3.||Prostheses and Implants (Prosthesis)